Colon Pharmaceutical announced at noon on June 5. The company recently learned that the company's holding subsidiary Colun Botai entered into a placement agreement with 2 placement agents on June 5 in accordance with the general authorization of its shareholders' meeting to issue shares. According to the agreement, the placement agent agreed to facilitate the placement of 5.918 million shares of Collombotte H shares to no less than 6 undertakers at a placement price of HK$331.8 per share. The completion of this placement is subject to the fulfillment of a number of prerequisites agreed in the placement agreement. The net proceeds from this placement are estimated to be HK$1,943 million, which will be used for Columbite's product development, clinical trials, registration, manufacturing and commercialization; enhancing internal R&D technical capabilities, strengthening external cooperation and expanding the product pipeline portfolio; and supplementing working capital and general corporate use.

Colon Pharmaceutical announced at noon on June 5. The company recently learned that the company's holding subsidiary Colun Botai entered into a placement agreement with 2 placement agents on June 5 in accordance with the general authorization of its shareholders' meeting to issue shares. According to the agreement, the placement agent agreed to facilitate the placement of 5.918 million shares of Collombotte H shares to no less than 6 undertakers at a placement price of HK$331.8 per share. The completion of this placement is subject to the fulfillment of a number of prerequisites agreed in the placement agreement. The net proceeds from this placement are estimated to be HK$1,943 million, which will be used for Columbite's product development, clinical trials, registration, manufacturing and commercialization; enhancing internal R&D technical capabilities, strengthening external cooperation and expanding the product pipeline portfolio; and supplementing working capital and general corporate use.